TAS 3681

Drug Profile

TAS 3681

Alternative Names: TAS3681

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 01 Mar 2016 Phase-I clinical trials in Prostate cancer (Hormone refractory, Second-line therapy or greater, Metastatic disease) in USA (PO) after March 2016 (NCT02566772)
  • 01 Mar 2016 Phase-I clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in United Kingdom (PO) (NCT02566772)
  • 25 Sep 2015 Taiho Oncology plans a phase I trial for Prostate cancer (Metastatic disease) in USA and United Kingdom (NCT02566772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top